For mesenchymal stem cells under development, BioMimetics Sympathies licenses the rights for the development, manufacture, and sales in Japan and overseas or work on joint development. We address consultations about licenses by indication, area, and right from development seeds before proceeding to clinical studies to the development stage after proceeding to clinical studies.
In addition, we accept consultations about the license or transfer of know-how and patents owned by us.
Previous experience of licensing out
- Joint development agreement for serum-free media for mesenchymal stem cells (2013, Japanese pharmaceutical company)
- A technology for the diagnosis of the malignancy of ovarian cancer licensed out (MMP1) (2018, private)
For consultations with and inquiries regarding BioMimetics Sympathies Inc, please feel free to contact us from the designated page.